Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
百奧賽圖（北京）醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

NOTICE OF THE 2026 FOURTH EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2026 fourth extraordinary general meeting (the "**EGM**") of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") will be held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online at 2:00 p.m. on Tuesday, December 15, 2026 (Hong Kong time) for the following purposes of considering and, if deemed appropriate, approving the following resolutions.

ORDINARY RESOLUTIONS
(CUMULATIVE VOTING SYSTEM)

1. To consider and approve the proposed election of the following Directors (excluding independent non-executive Directors) as Directors of the third session of the Board:

   1.1. To consider and approve the proposed election of Dr. Shen Yuelei as an executive Director of the third session of the Board;

   1.2. To consider and approve the proposed election of Dr. Ni Jian as an executive Director of the third session of the Board;

   1.3. To consider and approve the proposed election of Mr. Wang Yongliang as an executive Director of the third session of the Board;

   1.4. To consider and approve the proposed election of Ms. Zhang Leidi as a non-executive Director of the third session of the Board; and

   1.5. To consider and approve the proposed election of Dr. Liu Hongkang as a non-executive Director of the third session of the Board.

2. To consider and approve the proposed election of the following independent non-executive Directors as Directors of the third session of the Board:

   2.1. To consider and approve the proposed election of Ms. Liang Qi as an independent non-executive Director of the third session of the Board;

2.2. To consider and approve the proposed election of Dr. Wang Xi as an independent non-executive Director of the third session of the Board; and

2.3. To consider and approve the proposed election of Mr. Fei Yiping as an independent non-executive Director of the third session of the Board.

Details of the above resolutions proposed at the EGM are contained in the Circular, which is available on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.biocytogen.com.cn).

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, November 26, 2026

Notes:

1. Unless the context otherwise stated, capitalized terms used in this notice shall have the same meanings as those defined in the circular (the "**Circular**") of the Company dated November 26, 2026.

   Registered H Shareholders are requested to provide a valid email address of himself/herself/itself or his/her/its proxy (except for the appointment of the chairman of the EGM) for the proxy to receive the login access code to participate online in the eVoting Portal.

   Registered H Shareholders will be able to attend the EGM, vote and submit questions online via the designated website (evoting.vistra.com) by using the username and password provided on the notification letter sent by the Company.

   Non-registered holders whose H Shares are held in CCASS through banks, brokers, custodians or HKSCC may also be able to attend the EGM, vote and submit questions online. In this regard, they should consult directly with their banks, brokers, custodians, nominees or HKSCC Nominees Limited through which their H Shares are held (as the case may be) (collectively the "**Intermediary**") and instruct the Intermediary to appoint them as proxy or corporate representative to attend and vote at the EGM electronically and in doing so, they will be asked to provide their email address, before the time limit required by the relevant Intermediary. Details regarding the eVoting Portal including the login details will be emailed to them by the Company's H Share Registrar, Tricor Investor Services Limited.

2. The register of H Shareholders of the Company will be closed from Thursday, December 10, 2026 to Tuesday, December 15, 2026, both days inclusive, in order to determine the eligibility of the H Shareholders to attend and vote at the EGM to be held at 2:00 p.m. on Tuesday, December 15, 2026. If H Shareholders wish to be eligible to attend and vote at the EGM, all transfer documents of H Shares accompanied by the relevant share certificates and transfer forms must be lodged with the Company's H Share Registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration before 4:30 p.m. on Wednesday, December 9, 2026. H Shareholders whose names appear on the register of H Shareholders of the Company on Tuesday, December 15, 2026 shall be entitled to attend and vote at the EGM.

3. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalf. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.

4. The instrument appointing a proxy must be in writing under the hand of a Shareholder or his attorney duly authorised in writing. If the Shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same on its behalf.

5. In order to be valid, the form of proxy for H Shareholders, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company's H Share Registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, or via the designated website (evoting.vistra.com) by using the username and password provided on the notification letter sent by the Company as soon as possible and in any event no later than 2:00 p.m. on Monday, December 14, 2026 (Hong Kong time) or not less than 24 hours before the time appointed for holding the above mentioned meeting or any adjournment thereof. Completion and return of a form of proxy will not preclude an H Shareholder from attending in person and voting at the EGM or any adjournment thereof, should he/she/it so wish.

6. All resolutions at the EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Stock Exchange and the Company in accordance with the Listing Rules.

7. Resolutions numbered 1 to 2 are ordinary resolutions and shall be passed by more than half of the number of shares held by the Shareholders with voting rights present in person or by proxy at the EGM. A cumulative voting system will be adopted, meaning that each Share held by a Shareholder shall carry the same number of votes as the number of Directors to be elected under the relevant group of resolutions, and such votes may be cumulated and cast for one candidate or allocated among different candidates in any combination. Specifically, (i) for the election of Directors (excluding independent non-executive Directors), each Shareholder shall be entitled to a number of votes equal to the number of Shares held by him/her/it multiplied by the total number of Directors (excluding independent non-executive Directors) to be elected. Each Shareholder may cast all such votes for one candidate for Directors (excluding independent non-executive Directors) or allocate such votes among different candidates for Directors (excluding independent non-executive Directors) in any combination; and (ii) for the election of independent non-executive Directors, each

Shareholder shall be entitled to a number of votes equal to the number of Shares held by him/her/it multiplied by the total number of independent non-executive Directors to be elected. Each Shareholder may cast all such votes for one candidate for independent non-executive Directors or allocate such votes among different candidates for independent non-executive Directors in any combination.

8. References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this notice, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.